Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Augusta University Research Institute, Inc.

Neither a doctor nor a teaching hospital

Research payments

$2,289,093

542 payments

Through program year 2025, Augusta University Research Institute, Inc. is reported as receiving $2,289,093 in research payments, across 542 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $217,766 109
2024 Research $456,610 38
2023 Research $316,074 49
2022 Research $420,326 104
2021 Research $211,822 70
2020 Research $339,055 76
2019 Research $327,440 96

Breakdown

Who paid Research payments · program years 2019–2025
  1. CSL Behring $704,095 124 payments
  2. Clovis Oncology, Inc. $420,425 19 payments
  3. Alkermes, Inc. $316,934 184 payments
  4. Smith+Nephew, Inc. $119,604 2 payments
  5. pharmaand GmbH $95,443 13 payments
  6. Global Blood Therapeutics, Inc. $79,767 15 payments
  7. Orion Corporation $69,862 13 payments
  8. Laborie Medical Technologies Corp. $61,488 2 payments
  9. Mitsubishi Tanabe Pharma Development America, Inc. $59,285 1 payment
  10. BeiGene, Ltd. $59,129 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding $579,934 35 payments
  2. A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) $515,868 32 payments
  3. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $104,645 82 payments
  4. A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder $101,198 39 payments
  5. Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 $78,768 43 payments
  6. A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness $68,822 79 payments
  7. Illuminate $61,488 2 payments
  8. A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury $59,285 1 payment
  9. Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS $47,972 8 payments
  10. A Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution $40,959 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record